Physician profile
Ali Saberi
NPI 1649495276
$12,114.37
in general payments reported to CMS, 2019-2025
48 companies · $50.23 in 2025
The $50.23 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $1,767 · 2021: $707 · 2022: $469 · 2023: $400 · 2024: $7,311 · 2025: $50.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,650 · Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,650.00 |
| Food and Beverage | $1,111.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reprise Biomedical, INC. | $5,795.77 | 2024 | Miro3d, Miromirotract, Miro3d Fibers |
| Mimedx Group, INC. | $1,158.46 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $460.15 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.83 | 2019-2021 | |
| Smith+Nephew, INC. | $407.74 | 2019-2023 | Pico, Renasys Touch, Grafix Pl |
| Pfizer INC. | $318.23 | 2019-2021 | |
| Organogenesis INC. | $278.53 | 2019-2023 | Puraply |
| Novo Nordisk INC | $263.02 | 2019-2021 | |
| Amarin Pharma, INC. | $256.39 | 2019-2021 | |
| Convatec INC. | $189.79 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $172.14 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.31 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.58 | 2019-2022 | |
| Aroa Biosurgery Incorporated | $145.89 | 2022-2024 | |
| Lilly USA, LLC | $140.19 | 2019-2021 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $132.54 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Abbvie INC. | $125.04 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $116.34 | 2019-2020 | |
| Amgen INC. | $106.34 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $104.89 | 2019-2020 | |
| Royal Biologics, INC. | $103.69 | 2024 | |
| Stryker Corporation | $99.84 | 2021 | |
| Astellas Pharma US INC | $94.18 | 2019-2020 | |
| Next Science LLC | $84.99 | 2023 | Xperience, Blastx, Surgx |
| Novartis Pharmaceuticals Corporation | $82.52 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $80.82 | 2019-2020 | |
| Allergan, INC. | $73.69 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $64.67 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.80 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $42.38 | 2021 | |
| Bioventus LLC | $36.74 | 2022 | |
| Melinta Therapeutics, LLC | $34.19 | 2021 | |
| Kci USA, INC. | $33.49 | 2021-2022 | |
| Phadia US INC. | $32.32 | 2019-2020 | |
| Gilead Sciences, INC. | $32.21 | 2019 | |
| Eisai INC. | $27.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.63 | 2019-2020 | |
| Hartmann USA, INC. | $25.80 | 2023 | Two Press |
| Abbott Laboratories | $22.48 | 2020 | |
| Hydrofera LLC | $21.81 | 2021 | |
| Esperion Therapeutics, INC. | $20.22 | 2021 | |
| Advanced Oxygen Therapy INC. | $18.94 | 2024 | Topical Oxygen Chamber For Extremities |
| Optinose US, INC. | $17.57 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.84 | 2019 | |
| Integra Lifesciences Corporation | $14.77 | 2019 | |
| Cashflow Solutions, LLC | $14.21 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White |
| Ethicon US, LLC | $13.60 | 2019 | |
| Zyla Life Sciences, INC. | $11.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Saberi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.